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ABSTRACT
Reelin is a large, extracellular glycoprotein that binds to several membrane receptors on neural
stem cells (HNSCs), neural progenitor cells (NPCs), and neuroblasts of mammals to direct their
migration. Previously, our lab established the presence of Reelin increased migration of wild-type
fetal-derived HNSC’s, both in vitro and in vivo. In addition, we demonstrated that Reelin protein
treatment also increases the formation of radial glia via Notch-1 signaling, in vitro. Radial glia are
precursors to NPCs, as well as a scaffold for neuroblast migration during cortical lamination.
Reelin has long been associated with Schizophrenia (SZ). Because post-mortem brains are limited
to describing the end-point of the disease, heterozygous haplodeficient Reelin knock-out (Reeler)
mice are used to model developmental aspects of SZ in vivo. However, SZ is a complex,
polyfactoral disease with a myriad of dysfunctional pathways that may have unforeseen effects on
Reelin signaling. K. Brennand et al. (2014) reported low Reelin mRNA expression and cellular
characteristics mirroring the Reeler mouse in induced pluripotent stem (iPS) cell-derived NPCs
and neurons from living SZ patients. Building upon this and our work with stem cells, here we
consider Reelin’s effects on migration of Reelin-deficient iPS cell-derived NPCs. Reelin treatment
of consists of secreted Reelin from transfected human embryonic kidney 293 cells (HEK 293) with
the pCRL RELN gene-containing plasmid created by G. D’Arcangelo (1997) and given to us by
T. Curran. Using the metric of cellular migration, this is the first time it have been shown that SZ
iNPCs are capable of receiving and reacting to extracellular Reelin. Due to our validation of this
model, further work using iPS cell-derived neural cells can confidently be used for future disease
modeling and drug discovery of Reelin-deficient SZ.
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I. INTRODUCTION
From commencement to completion, Reelin guides the development of the cortex, cerebellum, and
hippocampus via a ballet of intertwining pathways that scientists are still discovering today.
Previously our lab demonstrated increased formation of radial glia (progenitor cells that provide a
scaffold for migrating neurons) via Notch-1 signaling in wild type fetal-derived human neural
progenitor cells as a direct result of Reelin protein treatment.(1) Kim et al. (2002) determined Reelin
secretion is integral to the migration of NPCs, both in vitro and in the heterozygous Reelindeficient (Reeler) mouse model.(2) Reelin deficiency was established to be responsible for the
delayed dendritic growth in Reeler mice.(3) Additionally, Reelin was shown to promote long-term
potentiation (LTP) by altering glutamate receptor composition in the membrane.(4) As evidenced
by the both in vitro and in vivo experiments, disruptions in the Reelin signaling pathway lead to
deviations in the standard structure of the cortex and long-term changes in neuronal development
and maturation, as seen in Schizophrenia (SZ).

Reelin is a 388 kDa glycoprotein secreted into the extracellular matrix during mammalian brain
development by specialized neurons called “Cajal-Retzius cells” located in the marginal zone of
the cortex and the outer molecular layer of the dentate gyrus in the hippocampus.(5, 6) In adults,
Reelin is secreted by: 1) a subset of γ-aminobutyric acid (GABA)ergic interneurons in the cortex
(specifically horizontal cells in layer I, bitufted neurons in layers II-V, and Martinotti cells in layers
II-VI), 2) CA1 GABAergic interneurons in the hippocampus, 3) glutamatergic granular cells in the
cerebellum, and 4) neurons of the entorhino-hippocampal pathway that guide migrating neural
stem cells to the olfactory bulb (4, 6, 7) Reelin binds to α3/β1 integrin, very low density lipoprotein
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receptor (VLDLR), and apolipoprotein E receptor 2 (ApoER2) complexes on the target cell
membrane. Neural stem cells (NSCs), radial glia, neural progenitor cells (NPCs), neuroblasts, and
mature interneurons – specifically glutamatergic Purkinji cells in the cortex, GABAergic
chandelier and basket interneurons in the cortex, glutamatergic CA1 pyramidal neurons in the
hippocampus, and GABAergic interneurons in the cerebellum possess the protein machinery to
respond to Reelin. (2, 5, 7-9) Radial glia are progenitor cells that give rise to NPCs, as well as provide
the scaffold upon which the NPCs migrate.(1, 10, 11) The activation of VLDLR/ApoER2 recruits a
cytosolic adaptor protein, Disabled 1 (Dab1), which binds to the NPxY motifs at the tail of the
receptors.(12) Fyn and Src – SRC-family kinases (SFK) – phosphorylate and activate Dab1
initiating the majority of the Reelin pathway signal transduction.(8) As seen in Figure 1, the effect
on the cell varies and depends on the target cell type: NSC cultures respond with increased radial
glia formation(1); NPCs mature from multipolar cells to bipolar cells (13); immature neurons react
by extending their apical process to the marginal zone(14), then releasing the radial glia scaffold
and tangentially migrating(15, 16); and mature neurons will increase the total number, length, and
branching of dendrites(3), as well as form more dendritic spines (17). Furthermore, glutamatergic
neurons experience an improvement in synaptic plasticity due to increased N-Methyl-D-Aspartate
Receptor (NMDAR) subunit NR2B and α-amino-3-hydroxy-5-Methyl-4-isoxazolePropionic Acid
Receptors (AMPAR) in the synaptic cleft in the presence of Reelin.(9) Phosphorylation of Dab1
leads to its subsequent ubiquitination, a negative feedback that leads to a decrease in total protein
levels.(8)

2

Figure 1. Reelin Molecular Pathway. NICD: Notch-1 Intracellular Domain, BLBP: Brain
Lipid-Binding Protein, NCAM: Neural Cell Adhesion Molecule, α3β1: α3β1 integrin, Dab1:
DisABled 1, VLDLR: Very Low Density Lipoprotein Receptor, NUDEL: NUclear Distribution
protein nudE-like, Disc-1: Disrupted In Schizophrenia 1, ApoER2: Apolipoprotein E Receptor 2,
PSD95: Post-Synaptic Density 95, NMDAR: N-Methyl-D-Aspartate Receptor, NR2: NMDAR
subtype 2, AMPAR: α-amino-3-hydroxy-5-Methyl-4-isoxazolePropionic Acid Receptor, SFK:
Src-Family Kinase, PI3K: PhosphoInositide 3-Kinase, LIMK1: Lin11/Isl-1/Mec-3 Kinase, PKB:
Protein Kinase B, GSK3β: Glycogen synthase kinase 3 β, MAPT: Microtubule-Associated
Protein – Tau, CRKL: CT10 Regulator of Kinase-Like, Rap1: Ras-proximate-1, NCAD: Neural
CADherin

During typical cortical lamination, Cajal-Retzius cells in the marginal zone secrete Reelin forming
a concentration gradient – with the highest concentration of Reelin at the marginal zone and the
lowest at the ventricular zone.(6, 18) When Reelin reaches the ventricular zone, it prompts NSCs to
form radial glia creating a scaffold that stretches all the way to the marginal zone. The radial glia
asymmetrically divide producing NPCs. (18) Reelin promotes the NPC differentiation into bipolar
immature neurons, as well at their apical process extension and anchoring to the marginal zone.(14)
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The immature neurons then migrate up the radial glia scaffold toward the marginal zone.(18)
According to the “detach and go” model, when these immature neurons reach a high enough
concentration of Reelin, they stop and separate from the radial glia scaffold, then begin to
tangentially migrate using the anchored process as a positional guide and forming the subplate.(18,
19)

The next layer of migrating cells invade the subplate and then similarly migrate to their final

destination, as dictated by the Reelin concentration gradient. These neurons will differentiate into
pyramidal or horizontal neurons that form Layer VI of the cortex.(18) This process continues
creating the distinctive inside-out, organized stratification of the six laminae in the cortex of a
normal brain, as seen in Figure 2.

Figure 2. Lamination of the Cortex in the Presence and Absence of Reelin. Green-to-white
gradient: Reelin concentration gradient, CR: Cajal-Retiez cells, RG: Radial Glia, S: neuronal cells
to form the Subplate, 6: neuronal cells to form Layer VI, 5: neuronal cells to form Layer V, 4:
neuronal cells to form Layer IV, 3: neuronal cells to form Layer III, 2: neuronal cells to form Layer
II.

4

In postnatal mammalians, Reelin is responsible for continual migration of NSCs from the
subventricular zone and dentate gyrus of the hippocampus to the olfactory bulb.(20). During
neuronal maturation in the first few weeks after birth, Reelin activates the pathways directly
involved in the formation of dendrites and synapses, including dendritic spines and postsynaptic
densities.(17, 21, 22) The high number of dendritic arborizations and dendritic spines allows for the
adaptive ability of neurons to transduce novel information from the environment.(8, 17, 22, 23) It has
been noted that Reelin is also capable of facilitating the maturation of glutamatergic synapses and
enhancing long-term potentiation (LTP) via NMDAR subunit NR2 phosphorylation and increased
AMPAR insertion into the membrane.(9, 24, 25) Overall, it appears that Reelin is required for normal
maintenance of synaptic function, connectivity, and plasticity.

When Reelin is absent, as in the case of the homozygous Reelin knockout (Reeler) mouse, the
cortex laminae are in the reverse, outside-in order with a ‘superplate’ consisting of the subplate
and Layer VI combined with the marginal zone. The superplate forms because the neuroblasts are
able to migrate radially, but do not receive a signal to extend their apical process, detach from the
radial glia, or migrate tangentially to form the appropriate layer.(3, 19) The disorganized fashion of
the Reeler cortex suggests that neuronal fates are determined by the timing of their conception and
not their final location.(19) In homozygous Reeler mice, cerebellar hypoplasia and laminae defects
causes ataxia and their characteristic “reeling” gait.(5) Additionally, Reeler mice suffer from
learning deficits due to reduced LTP, altered dendritic spine morphology, and fewer total number
of dendritic spines.(26,

27)

Complete absence of Reelin in humans is a severe developmental

disorder with a life expectancy of 10yrs called Lissencephaly, literally meaning “smooth brain”.(28)
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However, both humans and mice can be haplodeficient, due to either inheriting a gene mutation
on a single allele (heterozygous) or a partial silencing of the wild type gene via methylation.(21)
One study suggests that prenatal stress alone is enough to methylate the Reelin promoter and downregulate its expression.(29) Others demonstrate reduced Reelin expression in offspring due to
maternal infection and inflammation during pregnancy.(30-32) The cortex of adult heterozygous
Reeler mice maintains its inside-out organization and appears phenotypically normal.
Furthermore, these animals do not experience ataxia and exhibit a normal gait.(6) However,
heterozygous Reeler mice display a delay in apical process formation during corticogenesis(3) and
the pups have fewer total dendritic spines in the cortex and hippocampus.(25, 27, 33) The subtle
temporal disturbances in development result in impairments in the formation and maturation of
synapses, increased neuronal packing density, decreased LTP, and diminished GABAergic
signaling(14,

25, 32, 34)

, which in turn lead to behavioral and cognitive abnormalities similar to

neuropsychiatric disorders, such as SZ(14). Mice and rats with either functionally less total Reelin
protein or impaired Reelin pathway activation present with: hyperactivity(29, 35-37), inability to
inhibit startle response after a prepulse warning(30, 34, 38), hyperanxiety(29, 30) or hypoanxiety(35, 37,
39)

, reduced sociability(30, 35, 39), and even impaired memory under some conditions. (25, 29, 31, 35, 37)

Although SZ is polyfactoral, impairments in the Reelin pathway have been consistently implicated.
Researchers have reported methylations(21, 40-42) and reoccurring polymorphisms(43-48) of the Reelin
gene in post-mortem SZ patient brains, as well as decreased Reelin mRNA and protein expression
throughout the cortex, hippocampus, and cerebellum.(48-52) Abnormal density and aberrant location
of interstitial white matter neurons(53) and Layer II pre-alpha cell clusters(54) found in the postmortem cortex of SZ patients suggests deviations in normal migration due to insufficient Reelin.
6

Layer III neurons exhibited decreased dendritic spine density and reduced neuropil density, thus
increasing cell packing density as compared to the control.(55, 56) In vitro, reelin-deficient SZ patient
iPS cell-derived mature neurons also demonstrate fewer, shorter, and less complex dendrites, as
well as weakened interconnectivity as compared to the wild type control.(57) The same cells were
recorded to have deficits in migration as NPCs.(58)

Human iPS cells have often been chosen as an in vitro alternative in the past due to their ability to
replicate human pathways that may be altered in animal cells. Numerous studies on iPS cells have
demonstrated the capabilities of this model to parallel the processes that occur inside both wild
type and disease-affected cells in vivo. (10, 11, 57, 59-64) Due to the nature of humans and their anatomy,
patient brain tissue samples can only be obtained, ethically, post-mortem. These samples are not
only difficult to acquire, but provide only a characterization of the endpoint stage of disease. In
addition, schizophrenic patient post-mortem samples have been characterized by proteomics and
transcriptomics, however the act of neuroblast migration cannot be observed nor treated with dead
tissue.(58, 61) Because of the limitations on experimental research in post-mortem samples, disease
modeling and drug discovery are often performed in an animal model. However, animal models
are restricted by non-human physiology and cellular signaling, as well as the inability to
communicate with humans when experiencing psychological symptoms of disease. In the case of
SZ, reeler mice are a model that provides only a single pathway deficiency, while SZ is a multifactorial disorder.(50,

62, 65-71)

However, iPS cells from a live patient have the capability to

demonstrate the specific phenotypic and molecular changes due to Reelin deficiency at any stage
of development within a disease that may contain multiple genetic defects. And yet, there have
been no studies have been conducted concerning the relationship between SZ iPS cell-derived
7

HNSC/NPC (iHNSC/iNPC) characteristics and Reelin. Using the metric of migration, we show
that SZ NPCs dysfunction can be rescued with Reelin.
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II. MATERIALS & METHODS
2.1 Cell Culture.
iPS Cell Culture: Reelin-deficient fibroblast-derived SZ iPS cells were acquired via the Coriell
Repository (GM23760B). Thawed at passage 25, these cells were originally grown on murine
embryonic fibroblast (Gibco, A24903) feeder layer following Coriell manual instructions in sterile,
tissue-culture treated T75 flasks (Corning, 430641). Stem cell media contained: 20% Knockout
Serum Replacement (KSR) (Gibco, 10828028), 1% MEM Non-essential amino acids (NEAA)
(Gibco, 11140050), 1:1,000 β-mercaptoethanol/2-mercaptoethanol (Gibco, 21985023), 50 ng/mL
recombinant basic Fibroblast Growth Factor (bFGF) (R&D Systems, 233-FB-01M) in Dulbecco's
Modified Eagle's Medium (DMEM)/F12 with L-glutamine, HEPES, and phenol red (Gibco,
11330032). Thawing required the addition of 10uM ROCK inhibitor y-27632 (Sigma, Y05031MG). After 3 passages with 1 mg/mL collagenase, cells were transferred to the mTeSR 1 system
(STEMCELL, 05850) following product manual protocol. Passaging was performed with ReLeSR
(STEMCELL, 05872) as per product manual protocol.
Neural Induction: After 5 passages in mTeSR, cells were transferred to neural induction medium
in a sterile T75 suspension flask (Thermo Scientific, 156800). Neural induction medium consisted
of 20% KSR, 10% CTS Glutamax I (Gibco, A1286001), 1% non-essential amino acids, 1:1000 βmercaptoethanol/2-mercaptoethanol, 400 ng/mL recombinant human Noggin (Gibco, PHC1506),
10 uM SB431542/ Transforming growth factor-β (TGF-β) inhibitor (Sigma, S4317-5MG), 2
ug/mL heparin sodium (Sagent Pharmaceuticals, NDC#25021 402-10), 20 ng/mL recombinant
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bFGF in Neurobasal Medium (Gibco, 21103049). Embryoid bodies were cultured in neural
induction media for 5 days, then transferred to HNSC media.
iHNSC Culture: SZ iPS cell-derived HNSCs (iHNSCs) were grown in sterile T75 suspension
flasks (Thermo Scientific, 156800) with HNSC medium: 0.50 U/mL heparin sodium (Sagent
Pharmaceuticals, NDC#25021 402-10), 20 ng/mL recombinant human epidermal growth factor
(EGF) (R&D Systems, 236-EG-01M), 20 ng/mL recombinant bFGF (R&D Systems, 233-FB01M), 2% B27 (Gibco, 17504044), 5% antibacterial/antimycotic (AB/AM) (Gibco, 15240062) in
DMEM/F12 with L-glutamine, HEPES, and phenol red (Gibco, 11330032) . SZ iHNSCs had a
50:50 media change once per week, or earlier if phenol red indicator suggested high amount of
growth. Depending on the size of the colonies, SZ iHNSCs were mechanically passaged with a
scalpel or enzymatically passaged with StemPro Accutase Cell Dissociation Reagent (Gibco,
A1110501) following product protocol. Passaging and splitting of flasks occurred once per week
or less, depending on the size and number of colonies.
Differentiated iHNSC Culture: SZ iNPCs and neurons were all differentiated and maintained in
tissue-culture treated flasks or plates, depending on the experiment, in Ntera-2 (NT2) medium:
10% fetal bovine serum (FBS) (Gibco, 16000044) and 5% AB/AM (Gibco, 15240062) in
DMEM/F12 with L-Glutamine, HEPES, and phenol red (Gibco, 11330032). Cells were fed twice
a week, depending on the color of the phenol indicator.
HEK293 cells Culture: Human embryonic kidney (HEK)-293 cells were maintained in sterile,
tissue-culture treated T75 flasks (Corning, 430641) in 10% FBS (Gibco, 16000044), 5% AB/AM
(Gibco, 15240062) in DMEM with glucose, L-Glutamine, sodium pyruvate, and phenol red
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(Corning, 10-013-CM). Cells were passaged with Trypsin-EDTA (Ethylenediaminetetraacetic
acid) (0.25%) with phenol red (Gibco, 25200056) once per week.
2.2 SZ Neural Differentiation Confirmation.
iHNSC and iNPC Confirmation via Reverse Transcriptase-Polymerase Chain Reaction (rtPCR): RNA was isolated from all cells samples using TRIzol Reagent (Invitrogen, 15596018),
Chloroform (Fisher, BP1145-1), Isopropanol (Sigma, 34863), 75% Ethanol (Sigma, E7023500ML), and RNase-free water (Cellgro, 46-000-CM), according to the TRIzol product manual.
Isolated RNA was converted to cDNA using the SuperScript III First Strand Synthesis System
(Invitrogen, 18080051). PCR amplification was done on an Eppendorf Mastercycler epgradient S
thermocycler and then run on an agarose gel. PCR for GAPDH, CD133 (a marker for stem cells),
and beta-III-tubulin (a marker for neuronal cells) was performed with the AmpliTaq Gold 360
DNA polymerase kit following their 50 uL reaction protocol. The PCR product was run in a 2%
E-gel with SYBR SAFE (Invitrogen, G521802), as per product manual protocol. The DNA ladder
was 100 bp GeneRuler Plus (Fermentas, SM0321).
Forward primer for GAPDH: ATGTCGTGGAGTCTACTGGTC.
Reverse primer for GAPDH: AGAGTGGGAGTTGCTGTTGAA.
Forward primer for CD133: CAGAGTACAACGCCAAACCA.
Reverse primer for CD133: AAATCACGATGAGGGTCAGC.
Thermocycler settings: 7 minutes at 95°C; 30 cycles of 25 seconds at 95°C, 30 seconds at 52°C,
45 seconds at 72°C; then 7 minutes of 72°C.
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Forward primer for beta-III-tubulin: AAGCCGCAGTGTCTAAACC.
Reverse primer for beta-III-tubulin: CCCGAAATATAAACACAAA.
Thermocycler settings: 7 minutes at 95°C; 30 cycles of 25 seconds at 95°C, 30 seconds at 42°C,
30 seconds at 72°C; then 7 minutes of 72°C.
iNPC Confirmation via Immunocytochemistry/Immunofluorescence (ICC/IF): SZ iHNSCs
were plated on a 12-well plate for 10 days in NT2 medium to differentiate. Samples were fixed
and permeablized with 100% methanol (Sigma, 34860-1L) at -20°C for 25 mins. Blocking and
dilution was performed with 5% BSA in Tris-Buffered Saline with 0.2% Tween (TBS-T). Rabbithost anti-Beta-III-Tubulin (BIIIT) antibodies (abcam, ab18207) at 1:2000 and mouse-host antiGlial Fibrillary Associated Protein (GFAP) antibodies (abcam, ab190288) at 1:1000 were coincubated overnight (O/N) at 4°C. Fluorescein Isothiocyanate (FITC)-conjugated donkey-host
anti-mouse antibodies (Jackson, 715-095-150) and Tetramethylrhodamine (TRITC)-conjugated
donkey host anti-rabbit antibodies (Jackson, 711-025-152) at 1:100 were incubated one hr at room
temperature (RT) in a humidified chamber. Vectashield anti-fade mounting medium with DAPI
(4',6-diamidino-2-phenylindole, dihydrochloride) (Vector Laboratories, H-1200) was applied and
the cells were imaged with a Zeiss AX10 fluorescent microscope.
2.3 Reelin Production and Concentration.
Plasmids: The full length Reelin-expressing pCRL plasmid was constructed by Gabriella
D’Archangelo (1995) and given to our lab by Tom Curran from St. Jude Children’s Research
Hospital, Memphis Tennessee.(6) The pCRL, pCDNA3.1 (Invitrogen, V79020), and pEGFP
(plasmid enhanced green fluorescent protein) (Invitrogen) plasmids were amplified via One Shot
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TOP10 Chemically Competent Escherichia (E.) coli (Thermo Scientific, C404003) LB broth
(Fisher, BP1426-500) with 0.1% Ampicillin (Gibco, 11593027) or kanamycin (Gibco, 11815024),
following product protocol for transformation. Plasmids were isolated using QIAprep Spin
Miniprep kit (Qiagen, 27104).
pCRL Confirmation via Enyzme Digestion: pCRL plasmid was verified via Fast Digest
Restriction Enzyme Digest for BamHI (Bacillus amyloliquefaciens H) (Thermo Scientific,
FD0054) and EcoRI (E. coli RY13) (Thermo Scientific, FD0274) endonuclease enzyme cut sites,
using the given manual protocol.
RELN Sequence Confirmation via PCR: RELN sequence was confirmed intact on the pCRL
plasmid via PCR using MyTaq Red Mix (Bioline, BIO-25043). Gels were made at 2% agarose
(Benchmark Scientific, A1705) with SYBR SAFE (Invitrogen, S33102). The O’GeneRuler 1 Kb
Plus (Thermo Scientific, SM1343) DNA ladder was used as the standard.
Forward primer for RELN: TGAGTTCTCGGGAGGAGAGA.
Reverse primer for RELN: GGCACTTCCCATGAAGAAAA.
Thermocycler settings: 10 minutes at 95°C, then 40 cycles of 15 seconds at 95°C and 1 minute at
60°C as per Ovadia and Shifman (2011).(48)
HEK293 Cell Transfection: HEK293 cells were transfected with pCRL and pCDNA 3.1 plasmids
in sterile, tissue-culture treated T150 flasks (Corning, 355001) with Lipofectamine 2000
(Invitrogen, 11668027) in OptiMEM (Gibco, 31985070) using the product sheet scaled up
appropriately. HEK293 cells were allowed to incubate in the transfection medium for 72 hr. Media
were collected after 1 week and concentrated via centrifugation using a 100K MWCO protein
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concentrator (Pierce, 88532). Reelin protein presence was validated first via dot blot, then with
western blot.
Reelin Secretion Confirmation via Dot Blot: Serial dilutions of transfected-HEK293 cellconditioned media (1:1, 1:5, 1:125, 1:625, 1:3125) were loaded into the wells of a 96-well BioDot dot blotter (Bio-Rad) on a nitrocellulose membrane (Bio-Rad, 162-0252) following the BioDot protocol. Membrane was blocked with 5% milk in TBS-T (tris buffer saline with 0.1% tween
20) for one hr at RT, incubated in 1:1,000 Mouse Anti-Reelin antibody [G10] (abcam, ab78540)
for two hr, then incubated in 1:10,000 Goat Anti-Mouse IgG H&L(immunoglobulin G heavy and
light chain) horseradish peroxidase (HRP)-conjugated antibody (abcam, ab6789) for one hr at RT.
Imaged with ECL substrate (Thermo Fisher, 32132 ) on a Kodak Image Station 4000mm PRO
imager.
Reelin Concentration: Whole media from transfected-HEK cells was collected and frozen at 80*C every 3 days for one month after transfection. Media was then thawed and concentrated in
20 mL batches via the 100K MWCO Pierce Protein Concentrator (Thermo Fisher, 88532) as per
the product manual. Media was spun at 3,000xg for 15 min intervals until 90-95% volume
reduction. The retentate was then stored at -80*C.
Reelin Secretion and Dab1 Phosphorylation Confirmation via Western Blot: SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) and western blots were performed via
the NuPAGE system: NuPAGE LDS (lithium dodecyl sulfate) Buffer (Invitrogen, NP0008),
NuPAGE Sample Reducing Agent (10X) (Invitrogen, NP0004), NuPAGE Antioxidant
(Invitrogen, NP0005), NuPAGE Transfer Buffer (20X) (Invitrogen, NP00061). For Reelin, 3-8%
Tris-Acetate Protein gels were used (Invitrogen, EA03752BOX) with NuPAGE Tris14

Acetate SDS Running Buffer (Invitrogen, LA0041) and the HiMark Pre-Stained Protein Standard
(Invitrogen, LC5699). 15 uL of conditioned media and 50 ug of concentrated protein in LDS were
put in each well of SDS PAGE gel, which was blotted onto a PVDF membrane. Blocking was
performed with 5% milk in TBS-T (0.2% tween 20) for one hr at RT. Antibodies used were:
1:1,000 Mouse Anti-Reelin antibody [G10] in 5% milk for two hr at RT and 1:10,000 Goat AntiMouse IgG H&L HRP-conjugated antibody in 5% milk for one hr at RT. For Dab1, 4-12% BisTris Protein gels were used (Invitrogen, NP0322BOX) with NuPAGE MOPS (3-(Nmorpholino)propanesulfonic acid) SDS Running Buffer (Invitrogen, NP0001) and the Novex
Sharp Pre-Stained Protein Standard (Invitrogen, LC5800). Cells were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer containing: 150 mM NaCl (Fisher Scientific, 764714-5), 1% NP-40 (Thermo Scientific, 85124), 0.5% sodium deoxycholate (Thermo Scientfic,
89904), 0.1% SDS (MP Biomedicals, 190522), 50 mM Tris-hydrochloride (Fisher Scientific,
BP153-1), pH 8.0 with fresh protease (Thermo Scientific, 88666) and phosphase inhibitors
(Thermo Scientific, 88667). Homogenates were centrifuged for 15 mins at 14,000 rcf in 4°C.
Protein concentration of supernatant was found with BCA (bicinchoninic acid) with BSA (bovine
serum albumin) (Thermo Scientific, 23227). 50 ug of protein in LDS was loaded into each well.
SDS PAGE gel ran for one hr at 200 V, then blotted onto PVDF (polyvinyldiene difluoride)
membranes for 75 mins at 30V on a cold plate to prevent overheating. Blocking was done with
5% BSA in TBS-T (0.2% tween 20) one hr RT. Antibodies are as listed: 1:10,000 Rabbit AntiDab1 (phospho Y232) antibody [EPR2247(2)] (abcam, ab126728), 1:15,000 Rabbit Anti-GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) antibody [EPR16891](abcam, ab181602), 1:2,000
Rabbit Anti-Dab1 (C-terminal) (Sigma, D1569), and 1:10,000 Goat Anti-Rabbit IgG H&L HRPconjugated antibody (abcam, ab97051) in 5% BSA. Primary antibodies were incubated O/N at
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4°C, while the secondary antibodies were incubated one hr at RT. All blots imaged with ECL
substrate on a Kodak Image Station 4000mm PRO imager. Blots were then quantified by
densitometry using ImageJ.
2.4 Migration Assays.
Wound Healing Assay with Doses of Concentrated Reelin Protein on Laminin: Each well of
a 96-well tissue-culture treated plate (Thermo Scientific, 1520380) was treated with 5 ug/cm2
laminin (Corning, 354232). Wells were scratched with a scalpel on the bottom for reference during
imaging. SZ iHNSCs were accutased into single cell suspension and plated in NT2 medium. Serum
differentiation was allowed to continue for 16 days, until a flat, uniform layer of with bipolar cells
became evident. Cells were incubated in DMEM only for 24 hr prior to treatment. One scratch was
made per well using a 200 uL micropipette tip and gently washed once with NT2 medium. Wells
were treated with the following conditions: whole pCRL-transfected HEK cell-conditioned media,
whole pCDNA-transfected HEK cell-conditioned media, 1:10 concentrated Reelin in fresh NT2,
1:10 concentrated control in fresh NT2, 1:30 concentrated Reelin in fresh NT2, 1:30 concentrated
control in fresh NT2, 1:100 concentrated Reelin in fresh NT2, 1:100 concentrated control in fresh
NT2, 1:300 concentrated Reelin in fresh NT2, 1:300 concentrated control in fresh NT2, 1:1,000
concentrated Reelin in fresh NT2, 1:1,000 concentrated control in fresh NT2. Wells were imaged
at 4x before and after 14 hr incubation with a Leica DM IL microscope. Area of wounds found
using MRI Wound Healing Tool on ImageJ.
Neuronal Migration Confirmation via ICC of Scratch Assay: Each well of the 96-well plate
from the migration experiment was pre-fixed with cold 4% paraformaldehyde (PFA) (50% final
concentration of media), and then fixed with total 4% PFA on ice. Blocking was performed with
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5% BSA in Phospate-Buffered Saline with 0.1% Tween (PBS-T) and 7.51 g/mL glycine (Fisher,
BP381-500). Rabbit-host anti-Beta-III-Tubulin (BIIIT) antibodies (abcam, ab18207) at 1:2000 and
mouse-host anti-Glial Fibrillary Associated Protein (GFAP) antibodies (abcam, ab190288) at
1:1000 were co-incubated O/N at 4°C. Fluorescein Isothiocyanate (FITC)-conjugated donkey-host
anti-mouse antibodies (Jackson, 715-095-150) and Tetramethylrhodamine (TRITC)-conjugated
donkey host anti-rabbit antibodies (Jackson, 711-025-152) at 1:100 were incubated one hr at room
temperature (RT) in a humidified chamber. DAPI (4',6-diamidino-2-phenylindole,
dihydrochloride) (Invitrogen, D3571) was applied as per product manual and the cells were
imaged with a Zeiss AX10 fluorescent microscope.
Chemotaxic and Invasion Assay with Whole Transfected HEK-Cell Conditioned Media:
Chemotaxic and invasion assays were performed on 10-day old SZ iNPCs in a 24-well insert with
a 12 um membrane (Millipore, PIXP01250). The chemotaxic assay was performed with 12
uncoated well inserts, while 12 were coated with 5 ug/cm2 laminin (as per product sheet) to provide
the extracellular matrix for the invasion assay. Cells were serum starved for 24 hr prior to
treatment. Cells were treated with either the control whole cell-conditioned media from pCDNAtransfected HEK cells or whole pCRL-transfected HEK cell-conditioned media for 24 hr in 37*C,
5% CO2. Then the top/inside of the cell inserts were wiped thoroughly with an autoclaved cotton
swab and gently washed with NT2 to ensure no cells were left within the insert. Culture medium
was replaced with NT2 and 10% alamarBlue. Samples were transferred to a 96-well plate at time
zero and at 24 hr, as well as a 0% reduction (fresh NT2 + 10% alamarBlue) and a 100% reduction
control (autoclaved fresh NT2 + 10% alamarBlue). The absorbance was read at 630 nm and 540
nm via microplate reader, and the % reduction calculated using the formulas given in the
alamarBlue product manual.
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Invasion Assay with Doses of Concentrated Reelin Protein:
Chemotaxic and invasion assays were performed on 19-day old SZ iNPCs in a 24-well insert with
a 12 um membrane (Millipore, PIXP01250) coated with 5ug/cm2 laminin, as per product sheet.
Cells were serum starved for 24 hr prior to treatment. . To ensure no cells had migrated through
during iHNSC differentiation, well insert bottoms were wiped gently with an autoclaved cotton
swab and then transferred to a fresh 24-well plate. Wells were treated for 24 hr in 37*C, 5% CO2
with the following conditions: whole pCDNA-transfected HEK cell-conditioned media, whole
pCRL-transfected HEK cell-conditioned media, 1:10 concentrated Reelin in fresh NT2, 1:100
concentrated Reelin in fresh NT2, 1:1000 concentrated Reelin in fresh NT2, 1:10,000 concentrated
Reelin in fresh NT2. Then the top/inside of the cell inserts were wiped thoroughly with an
autoclaved cotton swab and gently washed with NT2 to ensure no cells were left within the insert.
Culture medium was replaced with NT2 and 10% alamarBlue. Samples were transferred to a 96well plate at time zero and at 48 hr, as well as a 0% reduction (fresh NT2 + 10% alamarBlue) and
a 100% reduction control (autoclaved fresh NT2 + 10% alamarBlue). The absorbance was read at
630 nm and 540 nm via microplate reader, and the % reduction calculated using the formulas given
in the alamarBlue product manual.
alamarBlue Proliferation Assay: SZ iHNSCs were accutased into single cell suspension and
plated in NT2 medium at 2 x 104 cells/mL into a sterile 96-well tissue culture-treated plate (Costar,
3599). Cells were incubated at 37*C, 5% CO2 until adherence. NT2 media was replaced with
pCRL/pEGFP-cotransfected or pcDNA/pEGFP-cotransfected HEK cell-conditioned media and
10% alamarBlue. Absorbance was measured by microplate reader at time zero, one, two three,
five, six, seven, and 24 hr. 100% reduced alamarBlue was made via autoclave.
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III. RESULTS
3.1 Neural induction and serum differentiation of iPS cells.
iPS cell colonies derived from a SZ fibroblast sample via Oct4, Sox2, Klf4, and c-Myc
transfection were acquired and grown on MEFs. During neural induction, the iPS cell colonies in
20% FBS underwent morphological changes. Small, round, flattened colonies began to stick
together becoming large and globular (Figure 3). Once removed from the neural induction
medium, the cells were cultured in HNSC medium and passaged to keep the colonies small and
proliferating. During the first few passages, floating colonies were separated from larger,
partially differentiated, adherent unipolar and bipolar single cells. The adherent cells appear
morphologically similar to neuroblasts, thereby indicating the potential for differentiation into
neural subtypes. PCR on this sample confirms the presence of CD133 and BIIIT (Figure 4),
demonstrating that both HNSCs and neuronal cells are present in the culture.

Figure 3: Time course images of neural induction. A. iPS cell colonies in neural induction
medium for 2 days, 4x. B. Colony after 5 days in neural induction medium, 4x. C. Cell colonies
cultured and passaged in the manner of HNSCs for 20 days after neural induction. Images
representative of colonies in the culture vessel, 10x.
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Figure 4: rt-PCR product in DNA gel electrophoresis of differentiated iPS cells after neural
induction. Replicates came from the same iPS cell-derived HNSC culture. Neural induction was
extraordinarily effective, as some cells overshot the CD133-expressing HNSC stage to
differentiate into beta-III-tubulin (BIIIT)-expressing neurons.

The floating iHNSC colonies were cultured separately to prevent further differentiation. After
two passages, the iHNSCs were placed in media with 10% FBS to establish their ability to
differentiate. Figure 5 represents the morphological changes that occur over time during serum
differentiation of HNSCs. We can see small, spherical cells change into unipolar cells, then into
larger bipolar cells; and then finally, terminally differentiating in to a cell with long, numerous
processes. An ICC at day 10 of serum differentiation demonstrates bipolar immature neurons
stained with BIIIT in equal measure with broad astrocytes stained with GFAP (Figure 6). A
number of cells remained unstained except by DAPI, suggesting these cells were not yet
differentiated.
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Figure 5: Time course images of SZ iHNSCs during serum differentiation. Images
representative of whole cell culture, 10x. Scale bar: 100μm. A. Day 0. B. Day 1. C. Day 2. D. Day
3. E. Day 7. F. Day 20.

Figure 6: ICC of serum differentiated SZ iHNSCs at Day 10. Images representative of whole
cell culture. Neurons stained for beta-III-tubulin (red). Glia stained for glial fibrillary acidic protein
(green), 10x. Scale Bar: 20 μm.
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3.2 Confirmation of pCRL plasmid and HEK293 Co-transfection with pEGFP.
The pCRL plasmid was created 22 years ago by G. D’Archangelo and T. Curran(6), who gifted it
to the lab. To validate the continuing presence of the RELN gene and to detect any potential
degradation, rt-PCR was performed on amplified and isolated pCRL plasmid from four different
clones and the product ran in a DNA electrophoresis gel (Figure 7). All four clones demonstrate
a band at the expected size of 101 base pairs (bp), indicating the presence of the RELN gene. The
Fast Digest enzyme digest products for the pCRL plasmid at the BamHI and EcoRI cutsites were
also run through the same gel. The BamHI enzyme digest products resulted in two bands at
approximately the expected sizes of 10.6 and 5.4 kilobase pairs (kb), indicating a full digest of
the plasmid. However, the EcoRI enzyme digest demonstrates an incomplete digestion with a
strong band at ~10.6 and no band at the expected 400 bp; however, two bands appear
approximately at the expected size of 5.8/5.4 and 4.4 indicating an incomplete digestion. The
expected 5.8 and 5.4 bands are assumed to be too close together to be resolved. However, there
are no fragments at unexpected band sizes. This combined with the success of the PCR, BamHI
enzyme digest, and the lack of fragments when whole plasmid is loaded in the gel, we can
conclude that the pCRL gene was intact.
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Figure 7: RELN pCRL plasmid. A. Abbreviated map of pCRL plasmid. Illustration includes
only the EcoRI and BamHI cut sites used. B. Gel Electrophoresis of plasmid PCR product,
restriction enzyme digest products, and uncut plasmid

HEK293 cells were transfected with either pCRL + pEGFP or pCDNA3.1 + pEGFP and
monitored for eGFP expression for two days. After this point, the media was changed to standard
HEK293 cell culture media (Figure 8). To ensure the secretion of the pCRL protein product,
media was collected from each sample and a dot blot was performed (Figure 9A). The dot blot
presented with a small amount of background in the wells with pCDNA-transfected HEK293
cell-conditioned medium, perhaps due to the high amount of protein in FBS. However, the
pCRL-transfected HEK293 cell-conditioned medium appears to have a stronger reaction
indicating Reelin presence in this medium. To be certain, a western blot was performed on whole
medium, concentrated Reelin retentate, and the left over filtrate for two different collection times
for both the pCRL- and pCDNA-transfected HEK cell cultures (Figure 9B). The first collection
of medium seems to contain less Reelin than the second, from the cell cultures that were
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transfected with pCRL. This may be due to the first undergoing a freeze-thaw cycle, while the
second was fresh, or due to the cells secreting less Reelin protein in the initial days after
transfection. To ensure even distribution of Reelin protein product, the collections thereafter
were pooled for concentration and treatment. Nevertheless, Reelin protein can be seen at its three
expected band sizes (~388, ~280, ~160 kDa) faintly in the media and more strongly in the
retentates. As expected, there is no Reelin in the filtrates or in the pCDNA-transfected HEK293
cell-conditioned media retentates. The three band sizes are from the desired full-length Reelin
protein and its two cleaved isoforms.

Figure 8: pCRL and pEGFP co-transfected HEK 293 cells. Representative merged GFP and
brightfield images. A. 17 hr transfection, 10x. B. 41 hr transfection, 10x.
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Figure 9: Transfected-HEK293 cell Reelin protein expression. A. Dot Blot of pCRL (Reelin)
or pCDNA (Control) and pEGFP co-transfected-HEK293 cell-conditioned whole media in
dilution. (-) ctrl: technical negative control consisting of deionized water. (+) ctrl: technical
positive control consisting of pure anti-Reelin antibody. B. Western blot of two collections of
transfected HEK293 cell-conditioned whole Reelin media (Lanes 1 and 2), concentrated retentate
of Reelin media (Lanes 3 and 4), filtrate for Reelin media (Lanes 5 and 6), and concentrated
retentate of Control media (Lanes 7 and 8). Lanes 3 and 5 are from concentrating medium from
the sample in Lane 1. Lanes 4 and 6 are from concentrating medium from Lane 2. Lane 7 was
collected and concentrated at the same time as Lane 3. Lane 8 was collected and concentrated at
the same time as Lane 4.

3.3 iPS cell-derived NPCs’ molecularly respond to Reelin.
The first cytosolic protein modified in the Reelin signaling pathway is Dab1, which is activated
via phosphorylation of 5 different tyrosine residues, including Y232.(72) To ensure the Reelin
treatment has an effect within the cell, phosphorylated Dab1 was measured via SDS-PAGE and
western blotting. If we look only at phosphorylation (Figure 10), there is the same relative amount
in the SZ iNPC samples treated with concentrated Reelin transfected-HEK293 cell-conditioned
medium as those treated with concentrated pCDNA transfected-HEK293 cell-condition medium
(ANOVA, p = 0.16916, Fobserved(2.80698) < Fcritical (7.70864)). As it has been established, Reelin
targets Dab1 for degradation via polyubiquination as a negative feedback loop reducing the total
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amount of Dab1.(8) Although their differences were not significant in an LSD post-hoc test, can
see this general effect in the total Dab1 of the SZ cells treated with Reelin versus the control cells
(ANOVA, p = 0.09046, Fobserved(4.93499) < Fcritical(7.708647)). Once the relative total Dab1 protein
concentration is factored in, we see that there is more phosphorylated Dab1 per total amount of
Dab1 protein present in Reelin-treated SZ iNPCs (M = 3.53992, SE = 0.67720) than the Controltreated SZ iNPCs (M = 1.12071, SE = 0.21995) (LSD, p = 0.05, tobserved(2.41921) > tcritical, twotail(1.39788))

Figure 10: Dab1 Phosphorylation. A. Western blot of SZ iNPCs treated with pCRL-transfected
HEK293 cell-condition medium (Reelin-medium) versus pCDNA-transfected HEK293 cellcondition medium (Control-medium). B. Bar graph of adjusted relative densities of total Dab1,
Dab1-p-Y232, and Dab1-p-Y232 normalized to the total amount of Dab1. *p = 0.05

3.4 SZ iPS cell-derived NPCs have increased wound closure when treated with Reelin.
The most common and well-established assay performed when studying migration is the scratch
assay. It’s simple but elegant design allows for straightforward, accessible imaging and ICC. To
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investigate whether SZ iNPCs respond to Reelin, we plated iHNSCs at high confluence and
allowed them to differentiate until the formation a, relatively, uniform carpet of cells consisting
of mainly bipolar morphology. We, then, serum starved the cells for 24 hr before the scratch
occurred to prevent confounding data due to proliferation. Since the treatment is an unusually
large protein expressed via transfected-HEK 293 cells, we partially purified it via protein
concentration with a membrane that retains proteins over 100kDa. A dose assay was then
performed to find the optimal relative concentration of Reelin for migration. In all the dilution
sets – except 1:1000 – the Control-treated SZ iNPCs migrated significantly less than the Reelintreated SZ iNPCs (Figure 11) (LSD, p = 0.05: Reelin-medium v. Control-medium, tobserved, twotail(9.09820)

> tcritical, two-tail(3.75058); Reelin v. Control 1:10, tobserved(6.55384) > tcritical, two-

tail(3.72147);

Reelin v. Control 1:30, tobserved(8.46283) > tcritical, two-tail(3.79604); Reelin v. Control

1:100, tobserved(12.9099) > tcritical, two-tail(3.84566); Reelin v. Control 1:300 tobserved(9.49628) >
tcritical, two-tail(4.10019); Reelin v. Control 1:1000, not significant (ns), tobserved(3.02300) < tcritical, twotail(3.84566)).

The highest percent wound closure is seen when the concentrated Reelin-medium

was diluted 1:100 (M = 70.3951, SE = 1.16939), which is significantly higher than all the other
doses (LSD, p = 0.05: Reelin-medium v. 1:100 tobserved(4.02585) > tcritical, two-tail(2.05387); Reelin
1:10 v. 1:100, tobserved(4.85176) > tcritical, two-tail(2.06052); Reelin 1:30 v. 1:100, tobserved(3.73506) >
tcritical, two-tail(2.05156); Reelin 1:100 v. 1:300, tobserved(2.09460) > tcritical, two-tail(2.03887); Reelin
1:100 v. 1:1000, tobserved(7.57249) > tcritical, two-tail(2.08350)). The controls are overall similar,
regardless of dilution (ANOVA, p = 0.934453, Fobserved(0.258898) > Fcritical (2.299234)).
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Figure 11: Scratch Assay of Reelin-treated SZ iNPCs. A. Representative images of SZ iNPCs,
treated with 1:100 dilutions of concentrated pCRL-transfected HEK cell-conditioned medium
(Reelin 1:100) or pCDNA-transfected HEK cell-conditioned medium (Control 1:100), 4x. Scale
Bar: 100 μm. a. t(0hr), SZ iNPCs in Control 1:100. b. t(14hr), SZ iNPCs in Control 1:100. c. t(0hr),
SZ iNPCs in Reelin 1:100. d. t(14hr), SZ iNPCs in Reelin 1:100. B. Bar graph of percent wound
closure of SZ iNPCs, treated with whole or dilutions (1:10, 1:30, 1:100, 1:300, 1:1000) of
concentrated pCRL-transfected HEK cell-conditioned media (Reelin) or pCDNA-transfected HEK
cell-conditioned media (Control). *p = 0.05, ns – not significant

To verify that neurons were indeed migrating, we performed ICC on the scratch immediately
after the second set of photos was taken (t = 14 hr). Bipolar βIIIT-positive immature neurons are
seen within the healed scratch, as well as some GFAP-positive glia (Figure 12). Some cells
express both proteins, indicating they are neural cells that are not yet committed to a specific
fate.
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Figure 12: ICC of neurons in scratch assay. A. Representative image of scratch at t(14hr), SZ
iNPCs in Reelin 1:100, 4x. Scale Bar: 100 μm. B. ICC of SZ iPS-cell derived neurons migrating
into the wound in the presence of Reelin. Neurons stained with beta-III-tubulin (green). Glia
stained with glial fibrillary acidic protein (red), 10x. Scale Bar: 50 μm.

3.5 SZ iPS cell-derived NPCs demonstrate increased invasion when treated with Reelin.
During corticogenesis, neurons travel through the previous laminae of the cortex to form the next
layer into the Reelin gradient. While scratch assay are useful for visualization, chemotaxic and
invasion assays more accurately replicate the 3-dimensional, in vivo processes by which cells
migrate. To that end, SZ iNPCs were cultured inside a cell insert that was either coated with
laminin or not, then treated with Reelin-medium or Control-medium. Using the alamarBlue assay
for proliferation, we were able quantitatively measure how much migration occurred to the other
side of the insert. In Figure 13A you can see that with or without laminin coating, the Reelintreated SZ iNPCs migrated through the membrane significantly more than the Control-treated SZ
iNPCs. (LSD, p = 0.05: Reelin-medium v. Control-medium without laminin, tobserved, two-
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tail(3.75058)

> tcritical, two-tail(9.09820); Reelin-medium v. Control with laminin, , tobserved, two-

tail(22.43208) > tcritical, two-tail(9.09820).

Interestingly, while both Control-treated conditions

resulted in similar outcomes (LSD, ns, Control-medium without laminin v. with laminin, tobserved,
two-tail(6.014094)

< tcritical, two-tail(9.09820), the Reelin-treated iNPCs treated with laminin migrated

significantly more than the Reelin-treated iNPCs without laminin (LSD, p = 0.05: Reelinmedium without laminin v. with laminin, tobserved, two-tail(18.12433) > tcritical, two-tail(9.09820),
suggesting a synergistic effect between the two proteins. In the dose assay, we can see a pattern
similar to the doses during wound closure (Figure 13B). The most migration occurred at the
1:100 Reelin dose treatment (M = 42.9120, SE = 2.16437), which was significantly higher than
all the other conditions (LSD, p = 0.05; Reelin whole medium v. 1:100, tobserved, two-tail(5.94737) >
tcritical, two-tail(4.87795); Reelin 1:10 v. 1:100, tobserved, two-tail(17.7839) > tcritical, two-tail(4.87795);
Reelin 1:100 v. 1:1,000, tobserved, two-tail(9.99575) > tcritical, two-tail(4.51611); Reelin 1:100 v. 10,000,
tobserved, two-tail(6.12553) > tcritical, two-tail(4.51611). The Reelin whole medium (M = 36.9646, SE =
2.38307) the Reelin 1:1,000 (M = 32.9162, SE = 1.04009), and Reelin 1:10,000 medium (M =
36.7864, SE = 1.32409) conditions were all similar and their differences not significant. The
most unusual condition would be the Reelin 1:10, which demonstrates the least amount of
migration (M = 25.1281, SE = 0.3968086) perhaps due to the concentration of Reelin inducing
maturation and spine formation rather than migration. More research is required to discover the
point at which this chemical message switches from one to the other.
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Figure 13: Invasion Assay. A. Bar graph of adjusted average change in absorbance of alamarBlue
due to oxidation from SZ iNPCs, treated versus untreated +/- laminin. B. Bar graph of adjusted
average change in absorbance of alamarBlue due to oxidation from SZ iNPCs, treated dilutions of
concentrated pCRL- or pCDNA-transfected HEK cell-conditioned media

3.6 SZ iPS cell-derived NPCs do not show increased proliferation when treated with Reelin.
To ensure our results were due to migration and not confounded by the upregulation of
proliferation, an alamarBlue proliferation assay was performed. When cells proliferate, the acidic
byproducts result in increased reduction of the alamarBlue causing a color shift that can be
measure by absorbance. The more alamarBlue that is reduced, the lower the absorbance. We can
see in Figure 14 that SZ iNPCs treated with Reelin-medium grow at the same rate as those
treated with Control-medium (LSD, p = 0.05; time = 1 hr, tobserved, two-tail(0.003667) < tcritical, twotail(0.014671);

time = 2 hr, tobserved, two-tail(0.009267) < tcritical, two-tail(0.022248); time = 3 hr, tobserved,

two-tail(0.041067)
tail(0.057230);

< tcritical, two-tail(0.053876); time = 5 hr, tobserved, two-tail(0.0392) < tcritical, two-

time = 6 hr, tobserved, two-tail(0.039467) < tcritical, two-tail(0.057208); time = 7 hr, tobserved,
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two-tail(0.034533)

< tcritical, two-tail(0.059281); time = 24 hr, tobserved, two-tail(0.003467) < tcritical, two-

tail(0.073788))

Figure 14: Proliferation with Reelin Treatment. Line graph of adjusted average change in
absorbance of alamarBlue over time, treated versus untreated SZ iNPCs.
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IV. CONCLUSION
In order to study the role of Reelin in SZ, we used a Reelin-deficient iPS cell line derived from a
live SZ patient skin biopsy differentiated into NPCs. Initially, we established that the cell can
molecularly receive the external Reelin signal and activate the pathway via Dab1
phosphorylation (Figure 9). Since, these SZ iNPCs previously exhibited migration dysfunction
as compared to wild type cells under control conditions in vitro (57), we treated with exogenous
Reelin and measured changes in the SZ iNPCs’ cellular motility. These cells displayed increased
wound closure (Figure 11), increased chemotaxis across a membrane and increased invasion
through an ECM-coated membrane (Figure 13A). We noted that while glia are known for
migrating, neurons were also within the wound closure when treated with Reelin (Figure 12). In
addition, we saw there was an optimal concentration of Reelin for migration (Figure 11, Figure
13B). Lastly, Reelin-induced effects were shown to be due to migration and not proliferation
(Figure 14). Using the metric of cellular migration, we can see from this study that SZ iNPCs
are indeed capable of receiving and reacting to extracellular Reelin treatment.
Since SZ causes are polyfactoral presenting with a myriad of signs and symptoms, the field has
had a difficult time establishing models for mechanistic study. While the heterozygous Reeler
mouse is the established model for the field, it may not mechanistically recapitulate the complex
interplay involved with the Reelin pathway in SZ. Unknown parallel pathways in migration,
dendrite formation, or synapse function may prevent Reelin treatment in a way that is not
predictable by a mouse model. Post-mortem brains can tell us SZ patients have lower amounts of
Reelin protein in their cortex and DNA mutations that contribute to a disease, but sample
acquisition is limited to the end-point of the disease. Due to these restrictions and the complexity
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of the disease, it was previously unknown whether or not SZ patient living cells would even
respond to Reelin treatment or if Reelin treatment alone was sufficient to improve the disordered
phenotype. Filling this niche in our body of knowledge, iPS cells are capable of being
differentiated to any stage of development, while retaining the specific phenotypes and protein
expressions that contributes to the disorder. Future experiments with SZ iPS cells can further
discover the capabilities and limitation of Reelin pathway treatment for SZ with Reelin
deficiency.
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